Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04294043 · ClinicalTrials.gov registry record · Phase 1

IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)

A Phase 1 study of Nontuberculous Mycobacterium Infection, sponsored by Chris Goss.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
10
Study locations

NCT04294043: Recruiting Phase 1 study of Nontuberculous Mycobacterium Infection, sponsored by Chris Goss.

NCT04294043 is a Phase 1 study of Nontuberculous Mycobacterium Infection that is actively recruiting participants, run by Chris Goss. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04294043, a Phase 1 study of Nontuberculous Mycobacterium Infection, is actively recruiting participants, sponsored by Chris Goss.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to assess the safety and tolerability of two 5-day infusion cycles of IV gallium in adult patients with CF who are infected with NTM. Funding Source - FDA Office of Orphan Products Development (OOPD)

Primary Outcome

Proportion of patients experiencing one or more Adverse Events of Special Interest (AESI). AESIs include the occurrence of either (1) a serious adverse event (SAE) of grade 3 or higher including hospitalizations or (2) study drug discontinuation because of an AE.

Interventions

  • DRUG Gallium nitrate

Study Locations (10)

Alabama

  • University of Alabama at Birmingham - Birmingham

Colorado

  • National Jewish Health - Denver

Maryland

  • Johns Hopkins University - Baltimore

Minnesota

  • The Minnesota Cystic Fibrosis Center - Minneapolis

Ohio

  • Nationwide Children's Hospital - Columbus

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

South Carolina

  • Medical University of South Carolina - Charleston

Texas

  • University of Texas Southwestern - Dallas

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-06-17
Est. Completion 2027-03-31
Phase Phase 1
Chris Goss

6 total trials

What NCT04294043 shows while recruiting

NCT04294043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 1 condition, with Nontuberculous Mycobacterium Infection appearing as the primary indexed condition, and to 1 intervention - of which Gallium nitrate is the first listed.

NCT04294043 lists 10 locations in 10 states (Alabama, Colorado, Maryland).

Frequently Asked Questions

What is clinical trial NCT04294043 about?

NCT04294043 is a clinical study titled "IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)". The purpose of this study is to assess the safety and tolerability of two 5-day infusion cycles of IV gallium in adult patients with CF who are infected with NTM. Funding Source - FDA Office of Orphan Products Development (OOPD)

What is the current status of trial NCT04294043?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2021-06-17. Estimated completion is 2027-03-31.

What conditions does trial NCT04294043 study?

This clinical trial studies the following conditions: Nontuberculous Mycobacterium Infection.

What interventions are being tested in trial NCT04294043?

The interventions under investigation include: Gallium nitrate (DRUG).

Who is sponsoring clinical trial NCT04294043?

This trial is sponsored by Chris Goss, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04294043 being conducted?

This trial has 10 study locations across Alabama, Colorado, Maryland, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nontuberculous Mycobacterium Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04294043's enrollment target sits among peer trials

40 1131st of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04294043, the US trial registry maintained by the National Library of Medicine. NCT04294043 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.